SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, for the first time our study supports the use of nilotinib as first-line treatment in a homogeneous series of CML patients irrespective to the hOCT1 and ABCB1 genotypes, replicating data obtained in the largest, company-driven ENESTnd trial.